Cutting Back on HTN Meds Can Be Safe Without Losing BP Control

The OPTIMISE trial was meant to provide an evidence base, for highly selected patients, for cutting back on the multiple antihypertensive agents many receive to reach their blood pressure targets.
Medscape Medical News

Source link

Related posts

Golgin A4 in CSF and granulovacuolar degenerations of patients with Alzheimer disease


clinical neurology; +123 new citations


Spotlight on the July 17 issue


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World